Is Jenburkt Pharma overvalued or undervalued?

As of 4 July 2025, the valuation grade for Jenburkt Pharma has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently considered overvalued, with a PE ratio of 18.96, an EV to EBITDA ratio of 14.49, and a PEG ratio of 0.82. These figures suggest that while the company has strong earnings potential, its current market price does not reflect a favorable valuation compared to its earnings growth.
In comparison to its peers, Sun Pharma has a much higher PE ratio of 35.2 and an EV to EBITDA of 24.87, while Cipla is considered attractive with a PE ratio of 23.2 and an EV to EBITDA of 16.09. This highlights that Jenburkt Pharma's valuation is not only high relative to its own historical metrics but also when compared to its industry peers. Additionally, the company's stock has outperformed the Sensex over various time frames, including a 56.85% return over the past year, which may contribute to its current elevated valuation status.